

■ Prescription Pharmaceutical Products

Perengatinib Proposa (DISCL) P	PRODUCT	INDICATION ^{1,2}			TEF	RRITORY			PARTNER	
Religational programming (REG) Pre- pre- presidential programming (REG) Pre- presidential programming (REG) Pre- presidential programming (REG) Pre- presidential presidential presidential presidential pre- presidential presidential presidential pre- presidential presidential pre- designation of the comment of the commen			Canada	Brazil	Argentina	Colombia	Mexico	Others		
Perengistration Perengistr	Oncology/Hematology									
Perengation Metastatic prolingocarcinome Marketed Marketed Marketed Pre-registration Pre-regis	Tafasitamab				registration	Pre-registration	Pre-registration	Pre-registration	Incyte	
delayed nausea and vomiting Prevention of acute nausea and vomiting Prevention of acute nausea and vomiting associated with moderately and highly engogenic cancer chemotherapy Prevention of acute nausea and vomiting associated with moderately and highly engogenic cancer chemotherapy Prevention of acute nausea and vomiting associated with moderately and highly engogenic cancer chemotherapy Prevention of acute nausea and vomiting associated with moderately and highly Refreshare Prevention of acute nausea and vomiting associated with moderately and highly Refreshare Prevention of acute nausea and vomiting Approved Refreshare Advanced prostate cancer Marketed Advanced prostate cancer Marketed Advanced prostate cancer Marketed	Pemigatinib	Metastatic cholangiocarcinoma				Pre-registration	Pre-registration	Pre-registration	Incyte	
Associated with moderately and highly emplored employ and proved employ and provided e	Akynzeo®	delayed nausea and vomiting	Marketed	Marketed	Marketed			Pre-registration	Helsinn	
registration Pre-registration Pre-registration	Aloxi®	associated with moderately and highly	Approved ³						Helsinn	
wereyn* breast cancer Marketed Advanced prostate cancer Marketed Marketed Celegene (BMS Abraxane*) Metastatic pancreatic cancer Marketed Marketed Marketed Marketed Marketed Eisal Officerentiated thyroid cancer and unresectable hepatocellular carcinoma Marketed Marketed Marketed Marketed Marketed Eisal Marketed Eisal Marketed Eisal Marketed Marketed Marketed Eisal Marketed Eisal Marketed Eisal Marketed Eisal Marketed Eisal Marketed Marketed Eisal Marketed Eisal Eisal Marketed Eisal Marketed Eisal Eisal Marketed Eisal Eisal Eisal Marketed Eisal Eisal Eisal Marketed Eisal	Fostamatinib	Treatment of chronic immune thrombocytopenia				Pre-registration	Pre-registration	Pre-registration	Rigel	
Abraxane* Metastatic prostate cancer Marketed Eisai Office International Properties of the phatocellular carcinoma Marketed Marketed Marketed Marketed Marketed Eisai Marketed Marketed Marketed Marketed Eisai Marketed Marketed Marketed Marketed Eisai Marketed Marketed Eisai Marketed Marketed Marketed Eisai Marketed Marketed Marketed Eisai Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Dr. Falk Dr	Nerlynx®		Marketed						Puma	
Abraxane* Metastatic pancreatic cancer Marketed Marketed Marketed Marketed Marketed Eisal Marketed Marketed Marketed Marketed Marketed Eisal Differentiated thyroid cancer and soft tissue sarcoma Marketed Marketed Marketed Marketed Marketed Eisal Marketed Marketed Eisal Marketed Marketed Marketed Marketed Eisal Marketed Marketed Marketed Eisal Marketed Marketed Marketed Eisal Marketed Marketed Marketed Eisal Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Eisal Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Eisal Marketed Marketed Marketed Own Own Marketed Eisal Marketed Marketed Marketed Own Own Marketed Eisal Marketed Marketed Marketed Own Own Marketed Marketed Marketed Marketed Own	Trelstar*	Advanced prostate cancer	Marketed						Debiopharm	
Alakevin Metastatic breast cancer and soft tissue sarcoma Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Markete	Vidaza®	Myelodysplastic syndrome		Marketed					Celgene (BMS)	
Differentiated thyroid cancer and unresectable hepatocellular carcinoma Advanced renal cell cancer Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Own Own Own Marketed Own	Abraxane*	Metastatic pancreatic cancer		Marketed					Celgene (BMS)	
hepstocellular carcinoma Marketed Marketed Marketed Marketed Esia Lenvima* Advanced renal cell cancer Marketed Esia Lenvima* Advanced renal cell cancer Marketed Esia Lenvima* Advanced renal cell cancer Marketed Marketed Marketed Esia Lenvima* Multiple myeloma; myelodysplastic syndrome Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Marketed	Halaven ®	Metastatic breast cancer and soft tissue sarcoma		Marketed	Marketed	Marketed		Marketed	Eisai	
Adevina* Multiple myeloma; myelodysplastic syndrome Marketed Marketed Own Adevina* Mantle Cell Lymphoma; follicular lymphoma Marketed Marketed Marketed Own Adevina* Metastatic prostate cancer Marketed Marketed Marketed Own Adevina* Metastatic prostate cancer Marketed Marketed Approved Own Adeptid* Palliative treatment of advanced prostate cancer Marketed Marketed Marketed Marketed Own Ambisome* Invasive fungal infection Marketed Marketed Marketed Marketed Marketed Marketed Basilea Invasive fungal infection Marketed Marketed Marketed Marketed Marketed Marketed Own Other Specialty Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease BS-C Marketed Marketed Marketed Marketed Marketed Marketed Own Parkinson's disease Marketed Marketed Marketed Marketed Marketed Or, Falk Ulcerative colitis Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Dr. Falk Woderate-to-severe dyspareunia Approved Marketed Marketed Marketed Marketed Orn Approved Moderate-to-severe dyspareunia Approved Marketed Marketed Marketed Marketed Orn Fibridoner* Idiopathic pulmonary fibrosis Marketed Marketed Marketed Orn Pesudomonas aeruginosa lung infection in patients with cystic fibrosis Severe acute or resistant chronic infections due to Pseudomonas Marketed Marketed Marketed Own Marketed Own Marketed Own Marketed Marketed Marketed Marketed Own Marketed Own	Lenvima®			Marketed	Marketed	Marketed		Marketed	Eisai	
Adevina* Multiple myeloma; myelodysplastic syndrome Marketed Marketed Marketed Own Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Marketed Own Marketed Marketed Approved Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Own Marketed Own Own Own Marketed Marketed Marketed Marketed Marketed Marketed Own	Lenvima®	Advanced renal cell cancer		Marketed	Marketed			Marketed	Eisai	
Adevina* Mantle Cell Lymphoma; follicular lymphoma Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Approved Own Acrifib* Relapsed or refractory multiple myeloma Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Own Marketed Marketed Marketed Marketed Marketed Marketed Own Infectious Diseases Ambisome* Invasive fungal infection Marketed Own Other Specialty Symptomatic treatment of mild to moderately severe demential in people with Alzheimer's and Parkinson's disease IBS-C Marketed Mar	BGx									
Marketed	Ladevina®	Multiple myeloma; myelodysplastic syndrome			Marketed	Marketed		Marketed	Own	
Approved Own Arketed Marketed Marketed Marketed Marketed Own Infectious Diseases Ambisome* Invasive fungal infection Marketed Own Other Specialty Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease Bis-C Marketed Marketed Marketed Marketed Marketed Marketed Marketed Own Discretal* Bis-C Marketed Marketed Marketed Marketed Marketed Marketed Own Ardelyx Salofalk* Ulcerative colitis Marketed Marketed Marketed Marketed Marketed Dr. Falk Ulscrofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Marketed Own Moderate-to-severe dyspareunia Approved Marketed Marketed Marketed Marketed Marketed Own Approved Marketed Marketed Marketed Marketed Marketed Own Discrofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Own Approved Marketed Marketed Marketed Marketed Own Discrofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Own Approved Marketed Marketed Marketed Marketed Own Discrofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Own Discrofalk* Primary biliary cirrhosis Marketed Marketed Marketed Own Discrofalk* Marketed Marketed Marketed Own Discrofalk*	Ladevina*	Mantle Cell Lymphoma; follicular lymphoma			Marketed			Marketed	Own	
Rembre® Palliative treatment of advanced prostate cancer Chronic myeloid leukemia Marketed Ma	Zyvalix®	Metastatic prostate cancer			Marketed	Marketed		Marketed	Own	
Infectious Diseases Ambisome* Invasive fungal infection Infectious Diseases Invasive fungal infection Infectious Diseases Invasive fungal infection Infectious Diseases Invasive fungal infection Invasive	Karfib*	Relapsed or refractory multiple myeloma			Marketed			Approved	Own	
Infectious Diseases Ambisome* Invasive fungal infection	Leprid®	Palliative treatment of advanced prostate cancer			Marketed				Own	
Ambisome* Invasive fungal infection	Rembre®	Chronic myeloid leukemia			Marketed	Marketed		Marketed	Own	
Invasive fungal infection Marketed	Infectious Diseases									
Marketed Own	Ambisome®	Invasive fungal infection		Marketed					Gilead	
Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease IBS-C Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Ulcerative colitis Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Dr. Falk Marketed Dr. Falk Marketed Dr. Falk	Cresemba*	Invasive fungal infection		Marketed	Marketed	Marketed	Marketed	Marketed	Basilea	
Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease IBS-C Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Ulcerative colitis Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Dr. Falk Marketed Dr. Falk Dr. Falk Marketed Dr. Falk	Impavido®	Leishmaniasis						Marketed	Own	
Severe dementia in people with Alzheimer's and Parkinson's disease IBS-C Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Ulcerative colitis Marketed Marketed Marketed Marketed Dr. Falk Ursofalk* Primary biliary cirrhosis Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Dr. Falk Marketed Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Marketed Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Marketed Marketed Dr. Falk Dr. Falk Marketed Dr. Falk Marketed Dr. Falk Dr. Falk Marketed Dr. Falk	Other Specialty									
Salofalk® Ulcerative colitis Marketed Marketed Marketed Dr. Falk Ulrsofalk® Primary biliary cirrhosis Marketed Marketed Marketed Dr. Falk Imvexxy™ Moderate-to-severe dyspareunia Approved TXMD Sijuwa™ Moderate-to-severe vasomotor symptoms due to menopause BGX Fibridoner® Idiopathic pulmonary fibrosis Marketed Marketed Own Foliscrin® DPI Pseudomonas aeruginosa lung infection in patients with cystic fibrosis Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli Fobradosa Chronic lung infections due to Pseudomonas Marketed Marketed Marketed Own Marketed Own Marketed Own Marketed Own Marketed Own Marketed Own	Exelon®	severe dementia in people with Alzheimer's and	Marketed	Marketed	Marketed	Marketed	Marketed	Marketed	Own	
Ursofalk® Primary biliary cirrhosis Marketed Marketed Marketed Dr. Falk Imvexxy™ Moderate-to-severe dyspareunia Approved TXMD Bijuva™ Moderate-to-severe vasomotor symptoms due to menopause BGX Fibridoner® Idiopathic pulmonary fibrosis Marketed Marketed Own Foliscrin® DPI Pseudomonas aeruginosa lung infection in patients with cystic fibrosis Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli Fobradosa Chronic lung infections due to Pseudomonas Marketed Marketed Marketed Own Marketed Own Marketed Own Marketed Own Marketed Own	Ibsrela®	IBS-C	Marketed						Ardelyx	
mvexxy™ Moderate-to-severe dyspareunia Approved TXMD Moderate-to-severe vasomotor symptoms due to menopause Moderate-to-severe vasomotor symptoms due to menopause Moderate-to-severe vasomotor symptoms due to Approved TXMD TXMD Marketed Marketed Own Toliscrin® DPI Pseudomonas aeruginosa lung infection in patients with cystic fibrosis Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli Tobradosa Chronic lung infections due to Pseudomonas Marketed Own Marketed Own	Salofalk®	Ulcerative colitis			Marketed	Marketed		Marketed	Dr. Falk	
Moderate-to-severe vasomotor symptoms due to menopause Approved Approved Approved TXMD	Ursofalk*	Primary biliary cirrhosis			Marketed	Marketed		Marketed	Dr. Falk	
## Approved ## App	lmvexxy™		Approved						TXMD	
Fibridoner* Idiopathic pulmonary fibrosis Marketed Own Foliscrin* DPI Secudomonas aeruginosa lung infection in patients with cystic fibrosis Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli Fobradosa Chronic lung infections due to Pseudomonas Marketed Own	Bijuva™		Approved						TXMD	
Pseudomonas aeruginosa lung infection in patients with cystic fibrosis Severe acute or resistant chronic infections due Toliscrin® 1-2 to colistin sensitive strains of gram-negative pathogenic bacilli Tobradosa Chronic lung infections due to Pseudomonas Marketed Marketed Own Marketed Own Marketed Own	BGx									
patients with cystic fibrosis Severe acute or resistant chronic infections due Foliscrin® 1-2 to colistin sensitive strains of gram-negative pathogenic bacilli Fobradosa Chronic lung infections due to Pseudomonas Marketed Marketed Own Marketed Own Marketed Own Marketed Own	Fibridoner®				Marketed			Marketed	Own	
Toliscrin® 1-2 to colistin sensitive strains of gram-negative pathogenic bacilli Tobradosa Chronic lung infections due to Pseudomonas Marketed Marketed Own	Toliscrin® DPI	patients with cystic fibrosis			Marketed			Marketed	Own	
	Toliscrin® 1-2	to colistin sensitive strains of gram-negative pathogenic bacilli			Marketed			Marketed	Own	
	Tobradosa Haler®	_			Marketed			Marketed	Own	

¹ Products in "pre-registration" have not yet been submitted for regulatory review and products in "submitted" are currently under regulatory review. The indication for all products classified as "pre-registration" or "submitted" is the anticipated indication upon regulatory approval.

² Refer to the "Products" section of Management's Discussion and Analysis for the three and nine-month periods ended September 30, 2022.

³ Knight will begin commercial activities following a transition period from Helsinn current licensees.